Benitec Biopharma Inc.

Equities

BNTC

US08205P2092

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
10.47 ^USD	+10.33%		+28.94%	+224.15%

May. 13	Benitec Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
Apr. 22	Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors	CI

Benitec Biopharma Limited Appoints Craig Lewis as Chief Medical Adviser

March 16, 2014 at 06:19 pm EDT

Benitec Biopharma Limited advised that Dr. Craig Lewis has agreed to serve as Chief Medical Adviser (part-time) on the company's non-small cell lung cancer (NSCLC) program. Dr. Lewis is medical oncologist at Prince of Wales Hospital.

Latest news about Benitec Biopharma Inc.

Benitec Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	May. 13	CI
Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors	Apr. 21	CI
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Apr. 18	MT
Top Midday Gainers	Apr. 18	MT
Top Premarket Gainers	Apr. 18	MT
Benitec Biopharma Inc. Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study	Apr. 18	CI
Benitec Biopharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 13	CI
JMP Securities Adjusts Benitec Biopharma's Price Target to $8 From $6, Keeps Market Outperform Rating	Jan. 24	MT
Benitec Biopharma Doses First Participant in Trial of Treatment for Oculopharyngeal Muscular Dystrophy	Nov. 30	MT
Benitec Biopharma Announces First Subject Dosed in Phase 1B/2A Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy	Nov. 30	CI
Earnings Flash (BNTC) BENITEC BIOPHARMA Posts Q1 Revenue $0M	Nov. 13	MT
Benitec Biopharma Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 13	CI
Certain Common Stock of Benitec Biopharma Inc. are subject to a Lock-Up Agreement Ending on 6-NOV-2023.	Nov. 05	CI
Benitec Biopharma Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-21	CI
Sector Update: Health Care Stocks Gaining in Late Afternoon Trading	23-08-11	MT
Sector Update: Health Care	23-08-11	MT
Benitec Biopharma Completes $30.9 Million Public Offering	23-08-11	MT
Top Midday Gainers	23-06-26	MT
Benitec Biopharma Receives FDA Clearance of IND for BB-301	23-06-26	DJ
Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy	23-06-26	CI
Earnings Flash (BNTC) BENITEC BIOPHARMA Reports Q3 Revenue $54,000	23-05-15	MT
Benitec Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-15	CI
Earnings Flash (BNTC) BENITEC BIOPHARMA Posts Q2 Revenue $14,000	23-02-13	MT
Benitec Biopharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-13	CI
Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program	23-01-23	CI

Chart Benitec Biopharma Inc.

Duration

Period

More charts

Company Profile

Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The Companyâs platform, DNA-directed RNA interference (ddRNAi), combines ribonucleic acid (RNA) interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is also engaged in developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The Company's BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a wildtype gene (to drive restoration of function in diseased cells).

Sector

Biotechnology & Medical Research

Calendar

2024-09-17 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

15.68 AUD

Average target price

23.94 AUD

Spread / Average Target

+52.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BENITEC BIOPHARMA INC.	+224.15%	88.98M
MODERNA, INC.	+41.79%	54.04B
IQVIA HOLDINGS INC.	-0.56%	41.92B
LONZA GROUP AG	+49.62%	41.96B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B

Other Biotechnology & Medical Research